Aggregator

Calorie labelling leads to modest reductions in selection and consumption

10 months 4 weeks ago

A new Cochrane review has found that calorie labelling of food on menus and products leads people to choose slightly fewer calories.

The research team, led by scientists from UCL, Bath Spa University, the University of Cambridge and the University of Oxford, examined evidence from 25 studies on the impact of calorie labelling on food selection and consumption. They found that calorie labels in supermarkets, restaurants and other food outlets led to a small reduction in the calories people selected and purchased. The average reduction was 1.8%, which would equate to 11 calories in a 600 calorie meal – or around two almonds.

Small daily changes in energy consumption can have meaningful effects if sustained long-term, and most adults tend to gain weight as we age. A UK government report estimated that 90% of 20-40 year olds in England will gain up to 9kg over ten years, and that reducing daily energy intake by 24 calories per day – roughly 1% of the recommended intake for adults – would prevent this increase.

Our review suggests that calorie labelling leads to a modest reduction in the calories people purchase and consume.

This may have some impact on health at the population level, but calorie labelling is certainly no silver bullet. Our previous version of this review from 2018 reported a potentially larger effect, but was inconclusive because there was significant uncertainty over the results. This update has reduced that uncertainty, and we can now say with confidence that there is very likely a real, albeit modest, effect.

- Dr Gareth Hollands, senior author, from the UCL Social Research Institute, also Senior Visiting Fellow at the University of Cambridge.

The new update compiles evidence from 25 studies with a strong emphasis on real-world field settings, with 16 of the studies being conducted in restaurants, cafeterias, and supermarkets. The studies that were analysed encompassed over 10,000 participants from high-income countries including Canada, France, the United Kingdom and the USA. Only two of the studies included alcoholic drinks, and their results were too uncertain to draw any meaningful conclusions.

This review strengthens the evidence that calorie labelling can lead to small but consistent reductions in calorie selection.

While the overall impact on individual meals or food purchases may be modest, the evidence is robust. The cumulative effect at a population level could make a meaningful contribution to public health, especially as calorie labelling becomes more widespread.

- Dr Natasha Clarke, lead author, from Bath Spa University, who began the project at the University of Cambridge. 

While calorie labelling shows promise, concerns remain about its possible impact on people at risk of disordered eating. The review noted a lack of data in the included studies on possible harms, including mental health impacts, and the authors recommend future research to assess this.

“Calorie labelling to reduce the calories that people consume remains somewhat contentious, both in terms of whether it has any effect, and whether potential benefits outweigh potential risks or harms,” says Gareth. “We can now say with considerable confidence that it does have a small but potentially meaningful effect on people’s food choices. Labelling may therefore have a useful role, ideally alongside a broader set of approaches that place more onus on industry rather than individuals, such as taxes, marketing restrictions and reformulation. However, we should not expect miracles, and any implementation of calorie labelling must balance the many potential positive and negative impacts of such policies.”

Clarke N, Pechey E, Shemilt I, Pilling M, Roberts NW, Marteau TM, Jebb SA, Hollands GJ. Calorie (energy) labelling for changing selection and consumption of food or alcohol. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: CD014845. DOI:10.1002/14651858.CD014845.pub2.

Thursday, January 16, 2025
Mia Parkinson

神経筋疾患によりふくらはぎの筋力が低下している人の歩行を改善するための足首の装具

10 months 4 weeks ago
神経筋疾患によりふくらはぎの筋力が低下している人の歩行を改善するための足首の装具 主なメッセージ 足首の装具(Ankle-foot orthoses:AFO)は、神経筋疾患によりふくらはぎの筋力が低下している人が歩くときの負担を軽減し、歩行速度と歩行時の満足感を向上させる可能性があるが、これらの結果については不確かである。 AFOが歩行の負担感、バランス、AFOの使用感、有害事象に及ぼす影響については、結論を出すことができない。 歩行の改善への影響は、AFOの素材によってさまざまであることが示唆されている。今後の研究で、この点をさらに深く調べることができるだろう。 なぜこの問題が重要なのか? 多くの神経筋疾患(つまり筋肉や筋肉を動かす神経の障害)によって、ふくらはぎの筋力低下が起こる。ふくらはぎの筋力は安全で効率的な歩行に欠かせないため、この筋力が衰えると歩き方が大きく変わってしまう。ふくらはぎの筋力が衰えると、歩行は不安定になり、より多くのエネルギーが必要となる。これにより、転倒や疲労感のような問題が起こる。 何を調べたかったのか? AFOは、神経筋疾患の人の歩行を改善するために処方される装具である。AFOにはさまざまな種類があり、歩行に対する影響もかなり異なっている。AFOを使用するとき、医療従事者と患者が十分な情報を得た上で決定できるように、歩行への影響に関する入手可能なエ...

Cochrane's Future of Evidence Synthesis Programme: A Transformation

10 months 4 weeks ago
Cochrane’s Future of Evidence Synthesis Programme has brought about some transformational changes

The arrival of 2025 means that we are now wrapping up our Future of Evidence Synthesis Programme, with several projects now closed and a few more due to wrap up by April 2025.

All aspects of the programme were designed to ensure that Cochrane is well-placed to meet rapidly shifting needs and challenges in global healthcare. It has been an ambitious programme that has introduced some important changes to how Cochrane develops, publishes, and shares its reviews.

A New Model for Synthesising Evidence

At the heart of this transformation is Cochrane’s new model for producing Cochrane evidence syntheses. The model retains many of the strengths that Cochrane’s reputation has been built on and added some new elements that will help to ensure Cochrane is sustainable and focused on major global health challenges now and into the future.

Evidence Synthesis Units and Thematic Groups

A key structural change has been the creation of Cochrane Evidence Synthesis Units and Thematic Groups, to help us address the world’s urgent health challenges more efficiently and collaboratively.

Cochrane Thematic Groups are topic-based collectives with specialist knowledge and expertise. They help identify priority areas, engage with key stakeholders, harness Cochrane’s global volunteer network and support the production and dissemination of high-quality Cochrane evidence syntheses. We have set up twelve Thematic Groups, each led by experts in their respective fields. Find out more.

Cochrane Evidence Synthesis Units are collaborative, multi-topic research groups, created to support delivery of trusted, timely Cochrane evidence to address major global health challenges. The geographic spread of the five new units reflects Cochrane’s commitment to producing evidence that helps to improve people’s health worldwide. Find out more.

Centralised Editorial Service

Cochrane’s Central Editorial Service has been scaled up to ensure an independent, and rigorous quality assurance process across all manuscripts and a more consistent experience for author teams. The Editorial Service works with Cochrane group members who contribute their expertise throughout the peer review process. Importantly, the centralisation eliminates conflicts of interest, with clear separation between manuscript development and editorial decisions. This ensures Cochrane reviews remain impartial, credible, and scientifically robust.

Simplifying the author journey

Cochrane’s authors are critical to Cochrane success – past and future – so through the Future of Evidence Synthesis programme we have introduced tools to make their experience smoother. The adoption of the Focused Review Format prioritises simplicity and clarity in review writing. This format reduces complexity for authors, speeds up review development time, and ensures Cochrane reviews communicate a clear message.

A major upgrade to RevMan, Cochrane’s authoring platform, has also taken place. The introduction of ‘study centric data’ streamlines data management, enabling authors to easily enter, reuse, and export data, reducing errors and saving time. Gone are the days of cumbersome back-and-forth data handling; authors can now focus on crafting compelling, well-supported reviews that inform global health decisions. Cochrane has expanded its resources for authors with dedicated roles, such as Evidence Synthesis Development Editors, to guide authors of high-priority review from planning to submission and offer expert advice on everything from scoping reviews to evaluating evidence quality. This hands-on assistance ensures Cochrane’s highest-priority reviews meet the highest standards while maintaining a personal touch.

Updated reporting standards and improved accessibility

A shift to the PRISMA guidelines for systematic reviews signals another step forward. Cochrane reviews now align with international standards, making them easier to produce and more user-friendly for their global audience. This transition reduces administrative burden while enhancing the clarity and accessibility of Cochrane’s output.

Additionally, systematic reviews produced in RevMan now come with downloadable data packages in formats like CSV, broadening the potential for research collaboration and reducing duplication. These changes solidify Cochrane’s commitment to Open Science, making its data transparent and accessible for the wider research community.

Global impact and inclusivity

With a renewed focus on inclusivity Cochrane seeks to ensure that its evidence reaches and benefits people everywhere. Evidence Synthesis Units in regions such as Nigeria and India reflect a deeper commitment to continue ensuring that our geographic representation in evidence synthesis is widespread and equal. Collaborations with global organisations like the World Health Organization (WHO) and local stakeholders in lower- and middle-income countries guarantee that Cochrane’s work addresses health inequities and meets diverse regional needs.

Inclusivity extends into the review process itself. With improved tools and simplified reporting standards, researchers from underrepresented regions and early-career scientists face fewer procedural barriers, increasing opportunities for collaboration and contribution to prioritise reviews that tackle globally significant issues.

Toward a brighter future for health evidence

The changes implemented as part of the Future of Evidence Synthesis Programme are not just about improving internal efficiencies, they are about creating a lasting impact. By adapting to a fast-changing scientific landscape, Cochrane can continue to contribute meaningfully to global health challenges now and in the future.

At a time of significant uncertainty, the Cochrane community has played an important role in the transformation. Together, community members have shown great resilience, ensuring these improvements address the real-world needs of practitioners, policymakers, and patients. These advancements not only secure Cochrane’s future but reaffirm its role as a bedrock of reliable health evidence in an uncertain world. For everyone who relies on trusted, accessible, and impactful health evidence, the changes brought by the Future of Evidence Synthesis programme are already making a difference. Cochrane is now better equipped than ever to deliver on its mission of improving health decisions - and people’s lives - worldwide.

Wednesday, January 15, 2025
Mia Parkinson

インセンティブ(報奨)は禁煙の促進に有効か、また長期的な効果はあるのか?

11 months ago
インセンティブ(報奨)は禁煙の促進に有効か、また長期的な効果はあるのか? 要点 ・世界において、喫煙は、病気と早期死亡の主要な、かつ予防可能な原因である。禁煙は、人々が健康で長生きするために極めて重要である。 ・インセンティブは、少なくとも6か月間禁煙を続けるのに有用である。 ・この効果はインセンティブの終了後も続き、長期的な効果が示唆されている。 ・インセンティブは、妊娠中の喫煙者が禁煙するのにも有用である。この効果は出産後も継続する。 インセンティブ(報奨)とは何か? 禁煙を奨励し、また禁煙を継続できた場合に与える報奨として、金銭、商品券、またはデポジットなどのインセンティブが利用されている。これらの制度は、職場や診療所で実施されることが多く、時には地域社会のプログラムとして実施されることもある。 何を調べようとしたのか? インセンティブを与えることが長期的な禁煙につながるかどうかについて評価を行った。 何を行ったのか? 成人を対象に、禁煙を促すためのインセンティブの提供について調査した研究を探した。参加者は、インセンティブを受諾するか、あるいは対照条件(通常の治療または別の禁煙介入)を受けるかについて無作為に割りつけられた。参加者には、さまざまな集団の人々や妊婦も含められた。 何がわかったか? 禁煙を支援するためのさまざまなインセンティブを試験した48件の研究が見つかった。...

Cochrane seeks Deputy Head of Communications

11 months ago

Title: Deputy Head of Communications
Specifications: Permanent – Full Time
Salary: £55,000 per annum
Location: (Remote) based in the UK, Germany or Denmark.
Directorate: Development Directorate
Closing date: 24 January, 2025

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information. The Deputy Head of Communications is an exciting new role that reflects the strategic importance of digital communications to this internationally renowned organization. It represents a rare opportunity to shape strategy, transform the charity’s digital presence, and experience working at a senior level when deputising for the Head of Communications.

You will create and implement the organization’s digital strategy, managing a team of experienced and dedicated web and communications specialists. Together you will deliver high-quality, targeted digital channels and marketing that inspire engagement and support from a range of stakeholder audiences.

Initial priorities will be to:

a) build digital communications capacity by recruiting three new roles (Digital Marketing Manager, Digital Marketing Officer and Copywriter);
b) develop a digital marketing strategy, based on a recent audit of channels and performance; and
c) establish and embed processes to ensure the relaunched Cochrane website is dynamic, useful and accessible to Cochrane’s key audiences.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everting we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect: 

  • An opportunity to truly impact health globally.
  • A flexible work environment.
  • A comprehensive onboarding experiences.
  • An environment where people feel welcome, heard, and included, regardless of their differences Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

  • For further information on the role and how to apply, please click here.
  • The deadline to receive your application is 24 January, 2025.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Read our Recruitment Privacy Statement.
Friday, January 10, 2025 Category: Jobs
Mia Parkinson

ニコチン・ベイプを止めるための最善の方法とは?

11 months ago
ニコチン・ベイプを止めるための最善の方法とは? 主な結果 テキストメッセージに基づく介入は、サポートなしまたは最小限のサポートと比較して、若者のベイプを止めるのに役立つ可能性があり、バレニクリンは、サポートなしまたは最小限のサポートと比較して、ベイプを止めるのに役立つ可能性があるが、より多くのエビデンスが必要である。 他の介入策がベイプをやめる手助けになるかどうかについては、もっと情報が必要だ。 介入策の潜在的な害や、それがタバコを吸う人の数に影響するかどうかについては、もっと情報が必要だ。 ニコチン入りベイプとは? ベイプ(電子タバコまたはe-シガレットとも呼ばれる)は、通常ニコチンや香料を含む液体を加熱する携帯機器である。液体は、使い捨てまたは詰め替え可能なカートリッジ、リザーバー、または「ポッド」に保存される。ベイプは、煙ではなく蒸気としてニコチンを吸入することができる。ベイプはタバコを燃やさないので、タバコを吸う人の病気の原因となる物質にさらされることは少ない。しかし、ベイプはベイプをしない場合よりも害を及ぼす可能性が高い。禁煙のためにニコチンを吸う人もいるが、ニコチンを吸う人の中にはタバコを吸ったことがない人もいる。ニコチンを含むベイプの使用をやめたいと思っても、ニコチンには中毒性があるため、なかなかやめられない人もいるだろう。 どのような介入が、人々がベイプを止めるの...

アスピリンに対する耐性を誘発する方法は、非ステロイド性抗炎症薬(NSAIDs)に対して過敏症のある成人にとって有効な治療法か?

11 months 1 week ago
アスピリンに対する耐性を誘発する方法は、非ステロイド性抗炎症薬(NSAIDs)に対して過敏症のある成人にとって有効な治療法か? 主要メッセージ • 非ステロイド性抗炎症薬(NSAIDs)に対して過敏症のある人における治療選択肢としてのアスピリン減感作(ATAD)(過敏症を誘発する薬(アスピリン)を少しずつ体内に取り入れ、アスピリンに対する耐性を誘発する方法、すなわちアスピリンに徐々に慣らしていく方法)の利益と有害性は、確実なエビデンス(科学的根拠)が不足しているため、不明なままである。 • ATAD療法は生活の質の向上につながるかもしれないが、そのエビデンスは小規模な研究から得たものである。 • 今後の研究では、手術や副腎皮質ステロイド(薬)(以下,ステロイド)使用の必要性に対し、アスピリン治療(アスピリン減感作療法)の明確な効果を実証するために、大規模な研究を行うべきである。 NSAID過敏喘息(NSAID不耐性、アスピリン喘息)とは? NSAID過敏喘息(N-ERD)とは、アスピリンやイブプロフェンなどのNSAIDsによって誘発される過敏症であり、鼻ポリープ(鼻茸、鼻や副鼻腔の粘膜の良性の腫瘍)や喘息を伴うまたは伴わない慢性の鼻副鼻腔炎(12週間以上続く鼻と副鼻腔の炎症)を合併している。N-ERDがある人にNSAIDを使用すると、30分から120分以内に鼻水、鼻閉(鼻づまり)...

Cochrane seeks Administrative Assistant

11 months 3 weeks ago

Title:  Administrative Assistant
Specifications: 12 month Fixed term contract – Full Time
Salary: £27,000 per annum
Location: (Remote) based in the UK, Germany or Denmark
Directorate: Evidence Production and Methods Directorate
Closing date: 10 January, 2025

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

This role provides effective and efficient administrative support the Cochrane Evidence Production & Methods Directorate (EPMD), primarily supporting the two Deputies and three Heads of the department.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally
  • A flexible work environment
  • A comprehensive onboarding experiences
  • An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. Cochrane has offices with payroll in the UK, Germany and Denmark.

How to apply

Monday, December 23, 2024 Category: Jobs
Harry Dayantis

Cochrane seeks Senior Administrative Officer (BGESC)

11 months 3 weeks ago

Title: Senior Administrative Officer (BGESC)
Specifications: 6 month Fixed term contract – Full Time
Salary: £35, 000 per annum
Location: (Remote) based in the UK, Germany or Denmark.
Directorate: Evidence Production and Methods Directorate
Closing date: 5 January, 2025

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.
As the BGESC Senior Administrative Officer, you will be key in providing high-level administrative, organizational, and logistical support to BGESC Project Manager, BGESC leadership team (four people) and to the Co-chairs of six international working/planning groups (approximately 20 people per group including Co-chairs).

This role is essential for ensuring the smooth execution of the ‘Building a Global Evidence Synthesis Community’ initiative, within a tight timeframe. By efficiently managing administrative tasks and optimizing processes, you will enable the Project Manager and leadership team to concentrate on strategic priorities and delivering key project milestones. The BGESC Administrative Officer will also provide support to BGESC Planning Clerks and Planning Analysts (nine people), who in turn work closely with the working/planning groups Co-chairs.

The BGESC project is part of the Wellcome Trust’s wider ‘Evidence Synthesis Infrastructure Collaborative’ initiative, but the successful candidate will be a Cochrane employee.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally
  • A flexible work environment
  • A comprehensive onboarding experiences
  • An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. Cochrane has offices with payroll in the UK, Germany and Denmark.

How to apply

Monday, December 23, 2024 Category: Jobs
Harry Dayantis

25歳までの若者の自傷行為や自殺を防ぐために、学校、大学で行われている活動(介入)は効果的か?

11 months 3 weeks ago
25歳までの若者の自傷行為や自殺を防ぐために、学校、大学で行われている活動(介入)は効果的か? 主な結果 - この疑問に答える研究は51件見つかったが、自傷行為を減らすための教育現場での介入の影響については不明確なままである。 - 有望な結果もあるが、それを確認するためには大規模な研究が必要であり、若者と共同で設計された、安全な環境で、長期間にわたって実施できるさまざまな介入アプローチの組み合わせを検討する研究が必要である。 自傷行為や自殺を防ぐには? 若者の自傷行為や自殺は、若者やその友人、一緒に過ごす他の若者、そして地域社会に苦痛を与える重大な公衆衛生の問題である。自殺や自傷行為を予防するための活動は、若者を守るスキル(技能)の構築など、変えることのできる要素に取り組むものである。活動は主に3つの種類がある。 「普遍的介入」とは、メンタルヘルスや自殺啓発教育プログラムのように、自傷行為や自殺予防に関する知識やスキル(技能)を高めることを目的としたものである。また、「普遍的介入」とは、問題解決能力のような、保護因子として働く特異的なスキルを教えるものである。これは否定的な態度や羞恥心を減らすのに役立ち、自殺願望があったり自傷行為に及んだりした場合に助けを求める可能性を高める。 「選択的介入」は、自殺願望があったり、自傷行為に及んだりしている人に気づき、支援を提供するものである。...

自分自身で記入する認知機能評価ツールは、どの程度正確に認知症を発見できるのだろうか?

11 months 3 weeks ago
自分自身で記入する認知機能評価ツールは、どの程度正確に認知症を発見できるのだろうか? 主な結果 - このエビデンスは、認知症の発見と診断に、自己記入式認知機能評価ツールを使用できることを示唆している。 - 一種類の評価ツールを他のものよりも推奨する十分なエビデンスはない。 - 診療所や家庭など、さまざまな環境におけるこれらの認知機能評価ツールの使用や、認知症を示すスコアについて、さらなる研究が必要である。 なぜ認知症の発見を改善することが重要なのか? 世界的に長寿化が進んでいるため、認知症と診断される人の数は今後大幅に増加すると予想されている。認知症の人が増えると、多大な医療や社会にかかわる費用をもたらすだろう。認知症は、日常生活に介助が必要になるまで記憶力が低下する永続的な症状である。正確で迅速な診断により、認知症の人やその家族は治療や支援を受けることができる。病態が存在するのに気づかなかった場合(偽陰性)、記憶、思考、行動を助ける治療を受けるのが遅れたり、ソーシャルワークや作業療法などの社会サービスからの支援を受けるのが遅れたりすることがある。認知症の誤った診断(偽陽性)は、検査を受けた人とその家族に精神的、心理的苦痛を与える可能性がある。現在、認知症の診断には専門のクリニックでの対面評価が必要であり、病歴、身体検査、血液検査、脳スキャンなどが検討される。 自己記入式認知機能...

Update on ‘Exercise therapy for chronic fatigue syndrome’

11 months 4 weeks ago

In 2019, Cochrane published an amended version of the review 'Exercise therapy for chronic fatigue syndrome’ and, at that time, announced an intention to further update the review. Due to insufficient new research in the field and a lack of resources to oversee this work, the update will not be proceeding.

Any feedback on this decision should follow Cochrane’s established complaints process. Any correspondence sent directly to individuals at Cochrane will not be considered.

Monday, December 16, 2024
Harry Dayantis

生徒の健康を向上させるための学校単位の方針と実践の改善

1 year ago
生徒の健康を向上させるための学校単位の方針と実践の改善 主な結果 - 学校やその職員は、支援する戦略が用いられた場合、生徒の健康的な食事、身体活動、肥満、タバコやアルコールの使用に対処するための介入をより適切に実施することができる。 - 学校とその職員がこうした介入策を実施するのを支援するためには、どの個別戦略が最適なのかを理解するために、さらなる研究が必要である。 - これまでの研究では、学校への実施支援による好ましくない影響は確認されておらず、その費用に関する情報も限られている。 知りたかったこと 5歳から18歳の生徒の食事、身体活動、肥満、タバコやアルコールの使用に対処するための学校単位の介入策の実施を支援するために、どのような戦略が有効であるかを知りたかった。例えば、学校食堂の運営者に対する教育や訓練(実施戦略)により、健康的でない食品の入手を減らし(実施結果)、生徒の食生活を改善するための健康的な食堂政策の実施(介入)を改善できるかどうか。また、費用対効果はあるのか、有害作用はないのか、などを知りたかった。その他の戦略の例としては、品質向上のための方法、学校の様子に関するフィードバック、注意書きや注意喚起、教育資源(マニュアルなど)などがある。 実施したこと 介入の実施を支援する戦略の使用したものとしていないものを比較した研究、あるいは2種類以上の異なる実施戦略を比較し...